ClinicalTrials.gg
Not yet recruitingNCT07851662FLEX-T1DUpdated Oct 1, 2026

Functional Mobility and Resistance Exercise for Postmenopausal Females With Type 1 Diabetes

An interventional study of Resistance exercise in Type 1 Diabetes (T1D) and Menopause, sponsored by Institut de Recherches Cliniques de Montreal. Not yet recruiting at 3 sites in Canada. Open to female participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Institut de Recherches Cliniques de Montreal · Not applicable, Interventional, and Prevention

How we know

Updated Oct 1, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
50 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Diabetes Mellitus, Type 1 by Institut de Recherches Cliniques de Montreal — 8 open to participants now, 8 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Institut de Recherches Cliniques de Montreal.

Planned enrollment
2nd of 38
63 · median 29
Started
2026
with 4 others
No phase
17 of 42
6 open now
Registered
42nd of 42
by date

Among the 42 studies in Diabetes Mellitus, Type 1 by Institut de Recherches Cliniques de Montreal, this one is the 2nd largest by planned enrollment of the 38 interventional ones that give a count, is one of 5 that started in 2026, is one of 17 with no phase, and was the 42nd registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

8 of the 42 studies in Diabetes Mellitus, Type 1 by Institut de Recherches Cliniques de Montreal are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 50 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Diabetes Mellitus, Type 1 by Institut de Recherches Cliniques de Montreal, or all of them as a file.
02

Study summary

Improvements in diabetes care and technology have led to people with type 1 diabetes living longer. There are now more seniors than ever living with this complex health condition. With aging, type 1 diabetes affects both bone (more brittle), and muscle (loss of size and strength). This loss happens faster and to a greater extent in females than in males, and greatly increases the risk of frailty and falls. It may also occur more quickly in individuals who have higher blood glucose (sugar) levels.

Frailty is an important factor to address. In older females, even mild frailty decreases the ability to perform day-to-day tasks, and increases the risk of fractures, falls, hospitalization, and even death. Performing regular exercise helps to maintain the strength and quality of both muscles and bones with aging. The best type of exercise to help maintain the ability to perform activities of daily living (known as functional mobility) for this population is currently unknown. Resistance exercise (weightlifting) helps to prevent decreases in mobility in seniors without diabetes. However, in the context of type 1 diabetes, high blood sugar levels could negatively impact these potential strength benefits and low blood glucose could lead to falls. As such, any exercise program that causes swings in glucose levels may hinder rather than help.

The goal of this study is to evaluate the effect of weightlifting over a 6-month timeframe on functional mobility in postmenopausal females with type 1 diabetes, compared to a group that does not train. the investigators will also assess its effects on blood sugar variability and the risk of hypoglycemia. Like different medications, not all exercise is equal. Creating more knowledge about the benefits of specific types of exercise in this population will allow us to be more precise in our exercise recommendations for living longer and more independently with type 1 diabetes.

Read the detailed description

Background: Type 1 diabetes, an autoimmune condition resulting in the near-absence of insulin secretion, requires lifelong exogenous insulin to manage blood glucose levels. Due to fear of hypoglycemia, which can be fatal, many people with type 1 diabetes maintain blood glucose levels slightly higher than the physiological range. This hyperglycemia is associated with many diabetes-related complications, including nephropathy, retinopathy, neuropathy and cardiovascular disease. It is also associated with an accelerated decrease in bone quality and muscle strength/quality with aging, creating a higher risk of age-related musculoskeletal fragility. The effects are more prominent in females than they are in males, particularly after menopause. As a result, postmenopausal females with type 1 diabetes have an especially high risk of frailty.

Frailty among older adults with type 1 diabetes is an important problem to address. With improvements in diabetes care/technology, people with type 1 diabetes are living longer, leading to a higher prevalence of type 1 diabetes among seniors. In older females without diabetes, even mild frailty decreases the ability to perform day-to-day tasks, and increases the risk of fractures, falls, hospitalization and even death. These risks may be accentuated for postmenopausal females living with type 1 diabetes. Regular exercise helps to maintain the strength and quality of muscles and bones with aging. The best type of exercise to help maintain functional mobility in postmenopausal females with type 1 diabetes while not sacrificing tight glycemic management is currently unknown. Resistance exercise (weight lifting) helps prevent decreases in mobility in seniors without diabetes. In people with type 1 diabetes it is often associated with smaller blood glucose declines than aerobic exercise during activity, but has also been reported to increase blood glucose levels in some situations.

It may also increase hypoglycemia occurrence in the hours after exercise. Hyperglycemia could negatively affect potential strength benefits. Frequent hypoglycemia increases the risk of falls and injury. Unfortunately, most of the available data were collected on young, fit males, limiting our ability to create evidence-based exercise guidelines for healthful and independent aging for postemenopausal females with type 1 diabetes. As there are known sex-related differences in physiological exercise responses and gender-related differences in activity preferences, studying females and males separately is warranted.

Goal: The goal of the study is to create knowledge around resistance exercise effects on functional mobility in postmenopausal females with type 1 diabetes. The investigators will also assess their impact on 24-hour glycemia (continuous glucose monitoring), bone mineral density (DXA) and self-reported quality of life. Finally, the investigators will compare these outcomes to a group who did not exercise during the same time frame.

Methods/Approaches: To achieve this goal, the investigators will conduct a 6-month randomized controlled trial across three sites to assess the impact of supervised resistance exercise on functional mobility (timed up and go test) compared to no exercise in postmenopausal females with type 1 diabetes. The investigators will recruit postmenopausal females with type 1 diabetes who are not currently meeting physical activity guidelines. All participants will undergo a 4-week run-in period for exercise familiarization and diabetes care optimization, followed by 22 weeks of the assigned treatment. Measures will be taken before run-in and at the end of the intervention by personnel blinded to group assignment.

Expected Outcomes: This project will fill an important void in the information being used to produce evidence-based guildeines for people with type 1 diabetes by providing more precise advice for postmenopausal females with type 1 diabetes.

03

Conditions studied

  • Type 1 Diabetes (T1D)
  • Menopause

Keywords

  • randomized controlled trial
  • resistance exercise
  • supervised training
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1) female
  • 2) clinical diagnosis of T1D requiring continuous insulin therapy [(either by multiple daily injections or continuous subcutaneous insulin infusion (insulin pumps)] for > 1 yr
  • 3) aged ≥60 yrs, or ≥50 yrs with signs or symptoms of clinical frailty (level 4 on the Clinical Frailty Scale)
  • 4) physically inactive (\<30 mins of aerobic activity \<3x/week; no resistance exercise)
  • 5) (no menstrual periods in the previous 12 months, or who have had a hysterectomy and bilateral salpingo-oophorectomy with ≥1 yr having elapsed since surgery)

Exclusion criteria

Exclusion Criteria:

  • 1) unable to communicate in English/French
  • 2) unwilling/unable to sign
  • 3) having performed RT in the past 6 months
  • 4) recent (last 3 months) or multiple episodes (>2 in last 12 months) of severe hypoglycemia and/or diabetic ketoacidosis
  • 5) those with PA restrictions due to:
  • a) intermittent claudication
  • b) severe peripheral neuropathy
  • c) active proliferative retinopathy
  • d) unstable cardiac or pulmonary disease
  • e) disabling stroke
  • f) significant renal disease (estimated \<25 mL/min/1.73 m2 or urine albumin/creatinine ratio >150 mg/mmol)
  • g) uncontrolled hypertension (BP>150 mmHg systolic or >95 mmHg diastolic while seated)
  • h) musculoskeletal injury, foot wound or amputation that would affect the ability to exercise
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
63 participants (estimated)

Study arms

  • Experimental
    Resistance exercise

    Supervised progressive resistance exercise training three times weekly

    Behavioral: Resistance exercise

  • No intervention
    wait-list control

    Usual care. Participants will be offered the training program at the end of the 6-month control period.

Interventions

  • BehavioralResistance exercise

    Supervised progressive resistance exercise

06

What researchers measure

Primary outcomes

  1. Change in the time (in seconds) taken to complete the timed up and go test test

    The test begins with the participant sitting correctly in a chair with arms fixed (so as not to move when the participant stands), with her back resting on the back of the chair. When the timer says "Go" the participant will stand, walk to a line 3 metres away from the chair, turn around, walk back and sit down. The timing starts with "Go" and ends when the participant is seated.

    Time frame: Baseline and 6 months (post-training)

Secondary outcomes

  1. change in 30-second chair stand test

    The number of full stands that can be completed in 30 sec with hands folded across the chest

    Time frame: Baseline and 6 months (post-training)

  2. Change in 6-minute walk test

    The number of meters walked around a set course in 6 minutes will be measured

    Time frame: Baseline and 6 months (post-training)

  3. Change in isometric grip strength

    Participants will stand with their arm at their side; elbow bent at 90 degrees. Applying the force in a smooth motion, they will squeeze a dynamometer as hard as possible for 5 secs. This test will be performed three times for each hand, with the average of the three measurements being recorded

    Time frame: Baseline and 6 months (post-training)

  4. Eight repetition maximum (8RM) strength test

    The participants will perform repetitions of the exercise as weight is gradually increased until the weight at which they can only perform 8 repetitions with good form. Exercises will include leg press and chest press.

    Time frame: Baseline and 6 months (post-training)

Other outcomes

  1. Bone density

    Measured using dual x-ray absorptiometry

    Time frame: Baseline and 6 months (post-training)

  2. Lean body mass

    Measured by dual x-ray absorptiometry

    Time frame: Baseline and 6 months (post-training)

  3. Short Form-36 Health Survey

    The questionnaire contains 36 items that assess 8 health domains: 1) Physical functioning, 2) role limitations due to physical health, 3) bodily pain, 4) general health perceptions, 5) vitality, 6) social functioning, 7) role limitations due to emotional problems, and 8) mental health. Each domain is scored from 0 to 100 with higher scores indicating better health status.

    Time frame: Baseline and 6 months (post-training)

  4. Diabetes-Specific Quality of Life Questionnaire (DSQOL)

    This is a patient-reported questionnaire designed to assess how living with type 1 diabetes affects quality of life. The English-language validated survey contains six factors: social aspects, fear of hypoglycemia, dietary restrictions, physical complaints, anxiety about the future and daily hassles. It contains 64 items with multiple subscales with respondents rating statements using a 1 to 6-point Likert-type response scale. Subscale scores are calculated separately. Higher scores generally indicate better diabetes-specific quality of life and greater treatment satisfaction.

    Time frame: Baseline and 6 months (post-training)

  5. Barriers to Physical Activity in Type 1 Diabetes (BAPAD-1)

    This questionnaire assesses perceived barriers to engaging in regular physical activity among adults with type 1 diabetes. It contains 12 items, each rated on a 1 to 7-point Likert scale. Higher scores indicate that the item is more likely to be a barrier to physical activity for the individual.

    Time frame: Baseline and 6 months (post-training)

  6. Diabetes Distress Scale (DDS-17)

    The survey contains 17 items, each rated on a scale of 1 (not a problem) to 6 (very serious problem). The four domains include emotional burden, regimen distress, physical-related distress, and interpersonal distress. The overall score is calculated by dividing the sum of the items scored by the total number of items, providing an overall score between 1 (no distress) and 6 (high distress).

    Time frame: Baseline and 6 months (post-training)

  7. Katz Index of Independence in Activities of Daily Living

    The questionnaire evaluates functional status by assessing independence in six basic activities: bathing, dressing, toileting, transferring (moving between bed and chair), continence and feeding. Each activity is scored as 1 (independent) or 0 (requires assistance or complete help). The scores are summed to produce a total score from 0 to 6, with 0-1 being severely dependent, and 6 being fully independent.

    Time frame: Baseline and 6 months (post-training)

  8. Clarke Hypoglycemia Awareness Questionnaire (Clarke Score)

    This is an 8-item questionnaire used to assess impaired awareness of hypoglycemia in people with type 1 diabetes. It contains 8 questions addressing: recognition of hypoglycemia symptoms, loss of warning symptoms over time, frequency of moderate hypoglycemic episodes, frequency of severe hypoglycemic episodes, frequency of symptomatic hypoglycemia, frequency of asymptomatic hypoglycemia, glucose level at which symptoms are perceived and confidence in recognizing low glucose levels by symptoms. Answers are classified as A (aware) or R (reduced awareness). A lower number of R scores indicates better awareness. A score of 4 or greater is considered clinically significant impaired awareness of hypoglycemia.

    Time frame: Baseline and 6 months (post-training)

  9. Pittsburgh Sleep Quality Index

    The PSQI measures an individual's perception of their sleep quality over the previous month. It contains 19 self-rated questions. It contains 7 component scores, each ranging from 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to create a global score ranging from 0 to 21, with lower scores indicating better sleep quality.

    Time frame: Baseline and 6 months (post-training)

  10. Diet

    3-day food diary

    Time frame: Week 3, 15, and 26

  11. Background physical activity

    7-day accelerometry measures

    Time frame: weeks 3, 15, and 26

  12. insulin dose

    self-reported

    Time frame: weeks 3, 15, 26

  13. changes in medication (other than insulin)

    self-reported changes in medication

    Time frame: weeks 3, 15, 26

  14. glucose time in range

    measured by continuous glucose monitoring

    Time frame: once per week between weeks 1 and 26

  15. glucose time below range

    continuous glucose monitoring

    Time frame: once per week between weeks 1 and 26

  16. level 1 hypoglycemia

    continuous glucose monitoring

    Time frame: once per week between weeks 1 and 26

  17. level 2 hypoglycemia

    measured by continuous glucose monitoring

    Time frame: once per week between weeks 1 and 26

  18. Severe hypoglycemia (level 3)

    continuous glucose monitoring

    Time frame: once per week between weeks 1 and 26

  19. time above range

    continous glucose monitoring

    Time frame: once per week between weeks 1 and 26

  20. Glycemic variability

    continuous glucose monitoring

    Time frame: once per week between weeks 1 and 26

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Sep 2030, 45 months later.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 45 months is above that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Oct 1, 2026
StartEst.
Dec 2026
Primary completionEst.
Sep 2030
CompletionEst.
Dec 2030
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07851662
Lead sponsor
Institut de Recherches Cliniques de Montreal
Responsible party
Jane Yardley (Director - Research Unit in Physical Activity and Diabetes, Institut de Recherches Cliniques de Montreal) — Principal investigator
First posted
Oct 1, 2026
Start date
Dec 2026 (estimated)
Primary completion
Sep 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Oct 1, 2026

Study contacts

Jane E Yardley, PhD
Contact
jane.yardley@umontreal.ca
1-514-987-5568
Corinne Suppere, MSc
Contact
csuppere@ircm.qc.ca
Jane E Yardley, PhD
principal investigator · Institut de Recherches Cliniques de Montreal

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion